88 related articles for article (PubMed ID: 1899689)
21. Heparin selectively inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells.
Hagège J; Delarue F; Peraldi MN; Sraer JD; Rondeau E
Lab Invest; 1994 Dec; 71(6):828-37. PubMed ID: 7807964
[TBL] [Abstract][Full Text] [Related]
22. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver.
Smedsrød B; Einarsson M
Thromb Haemost; 1990 Feb; 63(1):60-6. PubMed ID: 2160132
[TBL] [Abstract][Full Text] [Related]
23. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1.
Michel JB; Quertermous T
J Immunol; 1989 Aug; 143(3):890-5. PubMed ID: 2501387
[TBL] [Abstract][Full Text] [Related]
24. [Tissue plasminogen activator and plasminogen activator inhibitor in aqueous humor].
Giedrojć J; Stankiewicz A; Walkowiak M; Galar M; Bielawiec M
Klin Oczna; 1996; 98(4):283-5. PubMed ID: 9463119
[TBL] [Abstract][Full Text] [Related]
25. [Tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI)].
Hayashi T
Rinsho Byori; 1994 Apr; 42(4):346-51. PubMed ID: 8176842
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
27. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
28. Stimulation of tissue-type plasminogen activator synthesis by retinoids in cultured human endothelial cells and rat tissues in vivo.
Kooistra T; Opdenberg JP; Toet K; Hendriks HF; van den Hoogen RM; Emeis JJ
Thromb Haemost; 1991 May; 65(5):565-72. PubMed ID: 1908141
[TBL] [Abstract][Full Text] [Related]
29. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
30. Plasminogen activator inhibitor-1 and tissue-type plasminogen activator are up-regulated during unilateral ureteral obstruction in adult rats.
Ishidoya S; Ogata Y; Fukuzaki A; Kaneto H; Takeda A; Orikasa S
J Urol; 2002 Mar; 167(3):1503-7. PubMed ID: 11832778
[TBL] [Abstract][Full Text] [Related]
31. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator.
de Boer A; Kluft C; Kroon JM; Kasper FJ; Schoemaker HC; Pruis J; Breimer DD; Soons PA; Emeis JJ; Cohen AF
Thromb Haemost; 1992 Jan; 67(1):83-7. PubMed ID: 1615490
[TBL] [Abstract][Full Text] [Related]
32. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
Kluft C; Jie AF; Rijken DC; Verheijen JH
Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator system in smokers and non-smokers with and without periodontal disease.
Buduneli N; Buduneli E; Kardeşler L; Lappin D; Kinane DF
J Clin Periodontol; 2005 Apr; 32(4):417-24. PubMed ID: 15811061
[TBL] [Abstract][Full Text] [Related]
34. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass.
Chandler WL; Velan T
Thromb Res; 2003; 112(3):185-92. PubMed ID: 14967416
[TBL] [Abstract][Full Text] [Related]
35. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D
Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424
[TBL] [Abstract][Full Text] [Related]
36. Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
Leiper K; Croll A; Booth NA; Moore NR; Sinclair T; Bennett B
J Clin Pathol; 1994 Mar; 47(3):214-7. PubMed ID: 8163691
[TBL] [Abstract][Full Text] [Related]
37. Studies on the effect of fucosylated and non-fucosylated finger/growth-factor constructs on the clearance of tissue-type plasminogen activator mediated by the low-density-lipoprotein-receptor-related protein.
Camani C; Gavin O; Bertossa C; Samatani E; Kruithof EK
Eur J Biochem; 1998 Feb; 251(3):804-11. PubMed ID: 9490055
[TBL] [Abstract][Full Text] [Related]
38. The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells.
Camani C; Bachmann F; Kruithof EK
J Biol Chem; 1994 Feb; 269(8):5770-5. PubMed ID: 8119917
[TBL] [Abstract][Full Text] [Related]
39. Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
Bu G; Morton PA; Schwartz AL
J Biol Chem; 1992 Aug; 267(22):15595-602. PubMed ID: 1322401
[TBL] [Abstract][Full Text] [Related]
40. The receptor for tissue plasminogen activator (t-PA) in complex with its inhibitor, PAI-1, on human hepatocytes.
Wing LR; Bennett B; Booth NA
FEBS Lett; 1991 Jan; 278(1):95-7. PubMed ID: 1847116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
